Isarna Therapeutics dedicates itself to developing new therapies to improve patient outcomes with ophthalmic, fibrotic, or oncologic diseases.
Advanced Glaucoma / ISTH0036:
AMD/DME / ISTH0036:
For more information, please visit the US National Institutes of Health’s clinical trials registration website ClinicalTrials.gov.
ISTH0036 is a compound undergoing clinical development. ISTH0036’s use is restricted to patients enrolled in Isarna-sponsored clinical studies. The compound is not available for any other usage.